Mode
Text Size
Log in / Sign up

FeNO measurement shows limited diagnostic performance for asthma in school-age childrenFeNO breath test shows limited accuracy for diagnosing asthma in school-age children

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider FeNO's limited diagnostic performance for asthma in children, noting variability by allergic status.

This observational cohort study from the Swiss Paediatric Airway Cohort evaluated the diagnostic performance of fractional exhaled nitric oxide (FeNO) for asthma in 1,979 school-age children referred for suspected asthma. The reference standard was diagnosis by paediatric pulmonologists.

For asthma diagnosis, FeNO showed poor discrimination, with an AUC of 0.66 (95% CI 0.64-0.68). Asthma was diagnosed in 70% of the cohort. At a 25 ppb cut-off, sensitivity was 43% (95% CI 40-46) and specificity was 84% (95% CI 77-84). At a 35 ppb cut-off, sensitivity was 31% (95% CI 29-34) and specificity was 90% (95% CI 87-92). The positive predictive value at 35 ppb was 88%, and simulated at 30% prevalence was 57%.

Performance varied by subgroup. FeNO had no diagnostic value in non-sensitised children. In sensitised children with allergic rhinitis, the AUC was 0.59, while in those without rhinitis it was 0.68. Current inhaled corticosteroid use did not influence performance.

Safety and tolerability were not reported. Key limitations include that FeNO has limited diagnostic performance as a stand-alone test, performance varies by allergic sensitization and rhinitis status, and predictive values are affected by prevalence. Practice relevance is that FeNO has limited diagnostic performance for school-age asthma; interpretation should consider underlying prevalence and allergic characteristics.

This study looked at how well a breath test called fractional exhaled nitric oxide (FeNO) can diagnose asthma in school-age children who were referred for suspected asthma. The research involved 1,979 children in a Swiss cohort, and the reference for a true asthma diagnosis was made by pediatric pulmonologists.

The main finding was that FeNO had poor overall accuracy for diagnosing asthma, with a statistical measure of discrimination showing it was only slightly better than chance. The test was better at ruling out asthma (high specificity) than at confirming it (low sensitivity). Its ability to correctly identify children with asthma was especially low in those without allergic sensitization, where it showed no diagnostic value.

The study did not report any safety concerns, as it was a diagnostic accuracy study. The main reason to be careful is that the test's performance varies greatly depending on a child's allergy status and the local prevalence of asthma. This means the results may not apply to all groups of children.

From this single observational study, readers should understand that FeNO is not a reliable standalone test for diagnosing asthma in school-age children. Its usefulness may be limited, and interpretation should consider a child's specific allergic characteristics.

What this means for you:
FeNO breath test has limited accuracy for asthma diagnosis in children, especially those without allergies.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background Recent guidelines differ in how fractional exhaled nitric oxide (FeNO) is used to diagnose school-age asthma, either as one of several tests with a cut-off at 25 ppb or as a single rule-in test at 35 ppb. Evidence on its diagnostic performance and clinical utility in subgroups remain limited. Methods We analysed data from 1,979 school-age children in the Swiss Paediatric Airway Cohort referred for suspected asthma. We investigated FeNO performance with diagnosis by paediatric pulmonologists as reference standard using receiver operating characteristics curves, selected cut-offs and simulated predictive values across different prevalence. Subgroup analyses considered allergic sensitisation with allergic rhinitis and current inhaled corticosteroid (ICS) use. Results In the overall cohort (asthma diagnosis 70%), FeNO showed poor discrimination for asthma (AUC 0.66; 95% CI 0.64-0.68) with an optimal cut-off at 22 ppb. At 25 and 35 ppb, sensitivity was low (43%, 95% CI 40-46; 31%, 95% CI 29-34) and specificity moderate to high (84%, 95% CI 77-84; 90%, 95% CI 87-92). Positive predictive value at 35 ppb was 88% and was 57% when simulated at a prevalence of 30%. FeNO had no diagnostic value in non-sensitised children and lower performance in sensitised children with allergic rhinitis than in those without (AUC 0.59 vs 0.68). Current ICS use did not influence performance. Conclusion FeNO has limited diagnostic performance as a stand-alone test for school-age asthma, and underlying asthma prevalence and allergic characteristics should be considered in the interpretation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.